The landscape of U.S. immigration law is constantly shifting; don’t let this uncertainty impact your business.
It is crucial for employers to stay informed about the ever-evolving landscape of U.S. immigration laws and policies. This webinar will provide a comprehensive overview of the latest developments in immigration law, discuss the Trump administration’s executive orders and their impact on immigration and your business, review critical compliance requirements, and share proactive strategies for employers.
In this session, you will learn:
- A detailed review of current immigration enforcement activity impacting employers
- Analysis of recent policy changes and potential future developments
- Why you may want to review your “public space vs. private space” policies
- Strategies for preparing for ICE audits and worksite enforcement actions
- What types of enforcement actions to expect
- Best practices for mitigating legal risks
Join us and gain practical insights to ensure your business remains compliant and your workforce secure.
For a PDF of the presentation, please click here.
Webinar Recording
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.